Bionime Corp (4737) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bionime Corp (4737) has a cash flow conversion efficiency ratio of 0.005x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$9.99 Million ≈ $314.71K USD) by net assets (NT$2.21 Billion ≈ $69.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Bionime Corp worth for the company's overall valuation and market capitalisation.
Bionime Corp - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Bionime Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bionime Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bionime Corp ranked by their cash flow conversion efficiency. Explore 4737 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ugro Capital Limited
NSE:UGROCAP
|
-0.019x |
|
MCH Group AG
SW:MCHN
|
0.235x |
|
Duksan Hi Metal Co.Ltd
KQ:077360
|
-0.001x |
|
Ceres Global Ag Corp
TO:CRP
|
0.066x |
|
Gala Precision Engineering
NSE:GALAPREC
|
0.025x |
|
Kiler Gayrimenkul Yatirim Ortakligi AS
IS:KLGYO
|
0.001x |
|
Coast Entertainment Holdings Ltd
AU:CEH
|
0.081x |
|
Aroa Biosurgery Ltd
AU:ARX
|
0.045x |
Annual Cash Flow Conversion Efficiency for Bionime Corp (2009–2025)
The table below shows the annual cash flow conversion efficiency of Bionime Corp from 2009 to 2025. View Bionime Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.76 Billion ≈ $55.31 Million |
NT$494.80 Million ≈ $15.59 Million |
0.282x | +2626.07% |
| 2024-12-31 | NT$1.89 Billion ≈ $59.51 Million |
NT$19.53 Million ≈ $615.30K |
0.010x | -89.87% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.80 Million |
NT$203.44 Million ≈ $6.41 Million |
0.102x | +49.24% |
| 2022-12-31 | NT$2.08 Billion ≈ $65.55 Million |
NT$142.29 Million ≈ $4.48 Million |
0.068x | -47.36% |
| 2021-12-31 | NT$2.08 Billion ≈ $65.41 Million |
NT$269.72 Million ≈ $8.50 Million |
0.130x | +23.66% |
| 2020-12-31 | NT$2.07 Billion ≈ $65.24 Million |
NT$217.56 Million ≈ $6.85 Million |
0.105x | -46.98% |
| 2019-12-31 | NT$2.05 Billion ≈ $64.49 Million |
NT$405.56 Million ≈ $12.78 Million |
0.198x | +223.97% |
| 2018-12-31 | NT$1.99 Billion ≈ $62.79 Million |
NT$121.90 Million ≈ $3.84 Million |
0.061x | +329.29% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.46 Million |
NT$29.60 Million ≈ $932.53K |
0.014x | -91.95% |
| 2016-12-31 | NT$2.59 Billion ≈ $81.50 Million |
NT$457.84 Million ≈ $14.42 Million |
0.177x | +124.53% |
| 2015-12-31 | NT$2.54 Billion ≈ $80.08 Million |
NT$200.37 Million ≈ $6.31 Million |
0.079x | -70.49% |
| 2014-12-31 | NT$1.35 Billion ≈ $42.44 Million |
NT$359.84 Million ≈ $11.34 Million |
0.267x | +121.73% |
| 2013-12-31 | NT$1.07 Billion ≈ $33.73 Million |
NT$128.98 Million ≈ $4.06 Million |
0.120x | +411.49% |
| 2012-12-31 | NT$1.00 Billion ≈ $31.54 Million |
NT$23.57 Million ≈ $742.74K |
0.024x | -88.22% |
| 2011-12-31 | NT$1.09 Billion ≈ $34.19 Million |
NT$216.93 Million ≈ $6.83 Million |
0.200x | +1387.47% |
| 2010-12-31 | NT$1.02 Billion ≈ $32.02 Million |
NT$13.66 Million ≈ $430.40K |
0.013x | -95.85% |
| 2009-12-31 | NT$640.89 Million ≈ $20.19 Million |
NT$207.56 Million ≈ $6.54 Million |
0.324x | -- |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTE… Read more